Table 3. Pharmacological effects of mangiferin in vitro.
|
Cell lines |
Model drug (Toxins) |
MGF dose |
Treatment duration |
Results |
Ref |
|
HepG2 cells |
AGE-HSA |
10 µM |
2 h |
Inflammation (NF-қB)↓ |
[50] |
|
HepG2 cells |
NaAsO2 |
0 - 50 µM |
|
Inflammation (TNF-α)↓ |
[39] |
|
HepG2 cells |
|
10, 20, 40, and 80 µM |
24 h |
Antioxidants (Catalase, SOD, GPx, GST, GSH)↑ Oxidative stress (MDA)↓ |
[45] |
|
HepG2 cells |
NAFLD |
400 μM |
24 h |
Inflammasome (NLRP3)↓ |
[49] |
|
Primary hepatocytes |
GalN |
100 nM |
12 h |
Oxidative stress (ROS)↓ Apoptosis (Caspase 3)↓ Nrf2↑ |
[32] |
|
SCRHs |
TA3 |
10-200 µg/ml |
2 h |
Oxidative stress (ROS) ↓ |
[51] |
|
Primary hepatocytes |
LPS |
12.5, 25 and 50 μM |
1 h |
Inflammation TNF-α and IL-1β ↓ |
[44] |
|
Primary hepatocytes |
Pb(NO3)2 |
30, 40, 50, 60, 70 and 80 µg/ml |
2 h |
Antioxidants (GPx, GST, CAT, SOD)↑ Inflammation (NF-қB)↓ Apoptosis (Bcl-2↑, Bax↓) |
[47] |
|
Rat liver mitochondria |
Fe2+- citrate |
10 μM |
20 min |
Antioxidants (SOD, CAT)↑ Oxidative stress (MDA, ROS)↓ |
[11] |
|
Primary hepatocytes |
LPS |
- |
24 h |
ER stress (CHOP, GRP78) ↓ miR-20a/miR-101a↓ Nrf2↑ |
[52] |
AGE-HSA; Advanced glycation end products-Human serum albumin, CCl4; Carbon tetrachloride, D-GalN; D-galactosamine, FFA(II) nitrate, Bcl-2; B-cell lymphoma 2, GPx; glutathione peroxidase, GSH; glutathione, GST; glutathione S-transferase, LPS; lipopolysaccharide, MDA; malondialdehyde, NaAsO2; Sodium arsenite, NAFLD; Nonalcoholic fatty liver disease, NFκB; Nuclear factor kappa B, NLRP3; NLR family pyrin domain containing 3, ROI; Reactive oxygen intermediates, ROS; Reactive oxygen species, SCRHs; sandwich configuration of cultured rat hepatocytes, SOD; superoxide dismutase, TG; Triglyceride, TNF; Tumor Necrosis Factor, TPA; 12-O-tetradecanoylphorbol-13-acetate.